Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 5/20 | 0.35 |
| ▸ | CDK9 | P50750 | 4/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.32 |
| ▸ | CCNK | O75909 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191751 | 1.00 | CCNT1 (0.35) | CCNT1CDK9GRM4GRM2MAPK1 | |
| SCHEMBL1948800 | 1.00 | CCNT1 (0.35) | CCNT1CDK9GRM4GRM2MAPK1 | |
| SCHEMBL1192565 | 0.89 | CCNT1 (0.37) | CCNT1CDK9GRM4GRM2MAPK1 | |
| SCHEMBL1192581 | 0.89 | CCNT1 (0.40) | CCNT1CDK9GRM4CCNKHDAC1 | |
| SCHEMBL1192178 | 0.84 | CCNT1 (0.35) | CCNT1CDK9MAPK1CCNK | |
| SCHEMBL1192524 | 0.82 | GRM4 (0.33) | CCNT1CDK9GRM4GRM2MAPK1 | |
| SCHEMBL10179677 | 0.78 | GRM4 (0.37) | CCNT1CDK9GRM4GRM2MAPK1 | |
| SCHEMBL1463792 | 0.77 | CCNT1 (0.32) | CCNT1CDK9MAPK1 | |
| SCHEMBL1191828 | 0.77 | CCNT1 (0.42) | CCNT1CDK9GRM4GRM2CCNK | |
| SCHEMBL1946266 | 0.75 | ALDH1A1 (0.35) | GRM4MAPK1HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | CCNT1 47/4885CDK9 5/4885GRM4 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.